---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-034740"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2023-09-29T23:59:59+00:00"
generated_at: "2026-06-10T07:20:00.829173+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# AIM ImmunoTech enters amended research agreement with Roswell Park for Ampligen® studies

## Summary
- Agreement covers three clinical trials: melanoma, prostate cancer, triple-negative breast cancer.
- AIM will supply Ampligen® to Roswell Park for research projects at no cost.
- Term is three years from September 20, 2023, or until completion of research.
- Research may be funded by external entities (NIH, DOD, foundations); no financial terms disclosed.
- AIM retains ownership of Ampligen® and pre-existing IP; jointly developed inventions are shared.

## SEC filing metadata
- accession: 0001493152-23-034740
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2023-09-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315223034740/0001493152-23-034740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315223034740/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-034740
- JSON: https://secwatch.observer/filing/0001493152-23-034740.json
- Plain text: https://secwatch.observer/filing/0001493152-23-034740.txt

## Key facts
- Material Agreements
  AIM ImmunoTech Inc. entered into Amended and Restated Material Transfer and Research Agreement with Roswell Park Cancer Institute Corporation d/b/a Roswell Park Comprehensive Cancer Center (effective 2023-09-28).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Roswell Park Cancer Institute Corporation d/b/a Roswell Park Comprehensive Cancer Center
  - Effective: 2023-09-28
  source text: On September 28, 2023, AIM ImmunoTech Inc. (the “Company”) executed an Amended and Restated Material Transfer and Research Agreement (the “Agreement”) with Roswell Park Cancer Institute Corporation d/b/a Roswell Park Comprehensive Cancer Center (“Roswell”) that amends and restates the prior related agreements.
  evidence_url: https://www.sec.gov/Archives/edgar/data/946644/000149315223034740/0001493152-23-034740-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.